BioSpace News Archive

Working groups convened by ASCCP and made up of experts in cervical cancer, including representatives from nearly 20 professional organizations, are developing new Risk-Based Management Consensus Guidelines, an update to the 2012 Consensus Guidelines for Managing Abnormal Cervical Cancer Screening Test and Cancer Precursors.

Infiniti Research, a leading market intelligence solutions provider, has recently announced the completion of their latest market trend analysis for a company in the pharma packaging industry.

Two mass shootings in less than 24 hours on August 3-4, 2019, have ravaged the communities of El Paso, Texas, and Dayton, Ohio, and devastated our entire nation. In response to these most recent tragedies, the American College of Surgeons (ACS) expresses its ongoing grave concern about the death and destruction that these violent incidents continually inflict on American life.

Inaugurating a national annual program to recognize and honor individuals, companies and organizations that exemplify innovation and excellence to improve or transform health, advance educational opportunities and support economic empowerment, the Thought Leadership & Innovation Foundation (TLI) today announced two significant awards:

Second-Quarter 2019 Net Sales of $320.6 Million Increased 6 Percent; Second-Quarter 2019 GAAP Net Loss of $5.1 Million; Adjusted EBITDA of $124.1 Million

Nasdaq has granted the Company’s request for continued listing of the Company’s stock on the Nasdaq Stock Market.

The Co-operators and BDC Capital co-lead investment that will expand AI-driven infectious disease global early warning system

The Hyundai Hope On Wheels non-profit embarks on a nationwide tour this Summer to award new grants for pediatric cancer, surpassing $160 million in lifetime funding for research [07-August-2019] LAS VEGAS , Aug. 7, 2019 /PRNewswire/ -- Hyundai Hope On Wheels® (HHOW), a 501(c)(3) non-profit organization supported by Hyundai and its U.S. dealers, announces

Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced financial results for the second quarter and six months ended June 30, 2019 and provided a corporate update.

CartiHeal, developer of Agili-C™, a proprietary implant for the treatment of cartilage lesions in arthritic and non-arthritic joints, announced today the successful enrollment and operation of the first two patients in the Agili-C™ Investigational Device Exemption (IDE) pivotal study at Hospital for Special Surgery (HSS), New York, NY.